ReviewMayo Clinic proceedings2014
Cellular therapy for liver disease.
Review in Mayo Clinic proceedings, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 72 citations in OpenAlex.
- Review
- Emerging insights into mesenchymal stem cells and exosome-based therapies for liver injury.Biomolecules & biomedicine · 2025Review
- Article
- The Potential Hepatocyte Differentiation Targets and MSC Proliferation by FH1.Journal of cellular and molecular medicine · 2025Article
- Lesson learnt from 60 years of liver transplantation: Advancements, challenges, and future directions.World journal of transplantation · 2025Review
- Exploiting in silico modelling to enhance translation of liver cell therapies from bench to bedside.NPJ Regenerative medicine · 2024Review
- Isolation, culture, and delivery considerations for the use of mesenchymal stem cells in potential therapies for acute liver failure.Frontiers in immunology · 2023Review
- Role of Immune Cells in Biliary Repair.Frontiers in immunology · 2022Review
- A narrative review of liver regeneration-from models to molecular basis.Annals of translational medicine · 2021Review
- Cell therapy strategies for COVID-19: Current approaches and potential applications.Science advances · 2021Review
- Preclinical Application of Reduced Manipulated Processing Strategy to Collect Transplantable Hepatocytes: A Pilot and Feasibility Study.Journal of personalized medicine · 2021Article
- Role of Granulocyte Colony-stimulating Factor Therapy in Cirrhosis, 'Inside Any Deep Asking Is the Answering'.Journal of clinical and translational hepatology · 2019Review
- New Perspectives in Liver Transplantation: From Regeneration to Bioengineering.Bioengineering (Basel, Switzerland) · 2019Review
- Improvement of mesenchymal stromal cells and their derivatives for treating acute liver failure.Journal of molecular medicine (Berlin, Germany) · 2019Review
- A small molecule Hedgehog agonist HhAg1.5 mediated reprogramming breaks the quiescence of noninjured liver stem cells for rescuing liver failure.Translational research : the journal of laboratory and clinical medicine · 2019Article
- Endothelial cell fitness dictates the source of regenerating liver vasculature.The Journal of experimental medicine · 2018Article
- Progress in mesenchymal stem cell-based therapy for acute liver failure.Stem cell research & therapy · 2018Review
- Beneficial effects of naringenin in liver diseases: Molecular mechanisms.World journal of gastroenterology · 2018Review
- Highly efficient and expedited hepatic differentiation from human pluripotent stem cells by pure small-molecule cocktails.Stem cell research & therapy · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Regenerative medicine is energizing and empowering basic science and has the potential to dramatically transform health care in the future. Given the remarkable intrinsic regenerative properties of the liver, as well as widespread adoption of regenerative strategies for liver disease (eg, liver transplant, partial hepatectomy, living donor transplant), hepatology has always been at the forefront of clinical regenerative medicine. However, an expanding pool of patients awaiting liver transplant, a limited pool of donor organs, and finite applicability of the current surgical approaches have created a need for more refined and widely available regenerative medicine strategies. Although cell-based therapies have been used extensively for hematologic malignant diseases and other conditions, the potential application of cellular therapy for acute and chronic liver diseases has only more recently been explored. New understanding of the mechanisms of liver regeneration and repair, including activation of local stem/progenitor cells and contributions from circulating bone marrow-derived stem cells, provide the theoretical underpinnings for the rational use of cell-based therapies in clinical trials. In this review, we dissect the scientific rationale for various modalities of cell therapy for liver diseases being explored in animal models and review those tested in human clinical trials. We also attempt to clarify some of the important ongoing questions that need to be addressed in order to bring these powerful therapies to clinical translation. Discussions will cover transplant of hepatocytes and liver stem/progenitor cells as well as infusion or stimulation of bone marrow-derived stem cells. We also highlight tremendous scientific advances on the horizon, including the potential use of induced pluripotent stem cells and their derivatives as individualized regenerative therapy for liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.